Clinical Trial Update: SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SBRT+TACE+Sorafenib versus Sorafenib alone in unresectable hepatocellular carcinoma with portal vein thrombosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Thrombosis

Drugs mentioned

• SBRT+TACE+Sorafenib
• Sorafenib (Sorafenib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 3 | Status: UNKNOWN